New hope for tough head and neck cancers: experimental combo trial launches
NCT ID NCT07136545
First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests a new experimental drug called HCB101 combined with the immunotherapy pembrolizumab in 50 adults with head and neck cancer that has stopped responding to platinum chemotherapy. The goal is to see if the combination is safe and can shrink tumors. Participants receive weekly HCB101 infusions plus pembrolizumab every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HCB101 (an experimental drug) combined with pembrolizumab (an immunotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with head and neck cancer that has stopped responding to platinum chemotherapy.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply broadly. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang-Gung Memorial Hospital(Lin-Kou)
RECRUITINGTaoyuan, Guishan District, 333, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, Taipei City, 100, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, Taipei City, 112, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- New drug combo aims to shrink oral cancers before surgery
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New drug SKB571 takes on recurrent head and neck cancer